Research and Markets: Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013

Fri Jun 7, 2013 12:23pm EDT

* Reuters is not responsible for the content in this press release.

Research and Markets: Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013

Research and Markets (http://www.researchandmarkets.com/research/57zpxf/skin_and_skin) has announced the addition of the "Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013" report to their offering.

'Skin And Skin Structure Infections (SSSI) Caused By Bacteria - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.

Scope

- A snapshot of the global therapeutic scenario for Skin And Skin Structure Infections (SSSI) Caused By Bacteria.

- A review of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Skin And Skin Structure Infections (SSSI) Caused By Bacteria pipeline on the basis of route of administration and molecule type.

- Key discontinued pipeline projects.

- Latest news and deals relating to the products.

Companies Involved in Skin And Skin Structure Infections (SSSI) Caused By Bacteria Therapeutics Development

  • GlaxoSmithKline plc
  • Rib-X Pharmaceuticals, Inc.
  • Paratek Pharmaceuticals, Inc.
  • Affinium Pharmaceuticals, Inc.
  • Nabriva Therapeutics AG
  • Cempra Pharmaceuticals, Inc.
  • Trius Therapeutics, Inc.
  • Tetraphase Pharmaceuticals Inc.
  • Durata Therapeutics Inc.

Drug Profiles

  • dalbavancin
  • GSK-1322322
  • AFN-1252
  • AFN-1252
  • omadacycline tosylate
  • BC-7013
  • delafloxacin
  • radezolid
  • oritavancin disphosphate
  • fusidic acid
  • tedizolid phosphate
  • avarofloxacin
  • ABI-0043
  • eravacycline
  • Bismith-Thiol Compound For Acute Wound Infection

For more information visit http://www.researchandmarkets.com/research/57zpxf/skin_and_skin

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Immune Disorders

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.